Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak, K.M., Grudnik, P., Guzik, K., Zieba, B.J., Musielak, B., Domling, A., Dubin, G., Holak, T.A.(2016) Oncotarget 7: 30323-30335
- PubMed: 27083005 
- DOI: 10.18632/oncotarget.8730
- Primary Citation of Related Structures:  
5J89, 5J8O - PubMed Abstract: 
Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years. Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information ...